Orally administered EB-373 resulted in dose-dependent increase in psilocin blood concentration in pharmacokinetic (PK) animal studies, correlating to levels expected to be effective based on psilocybin data in humans Outcome…
Read More
New and enhanced manufacturing process now operational improving yield and purity of material and ease of process Enveric to expand existing manufacturing agreement with CDMO partner for enhanced supply of…
Read More
CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction…
Read More
CAMBRIDGE, Mass. - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and…
Read More
New composition of matter claims establish intellectual property for Enveric's EVM301 Series of novel small molecules designed to promote neuroplasticity without inducing hallucinations. CAMBRIDGE, Mass. - Enveric Biosciences, Inc. (NASDAQ:…
Read More
CAMBRIDGE, Mass. - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and…
Read More
New composition of matter claims expands intellectual property for Enveric's EVM201 Series CAMBRIDGE, Mass. - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the…
Read More
Research highlights the potential of Enveric's EVM201 Series aimed at developing psilocin prodrugs with altered metabolic profiles that offer superior administration and treatment benefits, but reduce pharmacological exposure CAMBRIDGE, Mass.…
Read More
CAMBRIDGE, Mass. - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and…
Read More
Intellectual property describes composition of matter claims governing Enveric's lead clinical candidate, EB-373, which is being developed for the treatment of anxiety disorder CAMBRIDGE, Mass. - Enveric Biosciences, Inc. (NASDAQ:…
Read More
